Targacept, Inc.
200 East First Street
Suite 300
Winston-Salem
North Carolina
27101-4165
United States
Tel: 336-480-2100
Fax: 336-480-2107
Website: http://www.targacept.com/
About Targacept, Inc.
Targacept, Inc. is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, a unique class of proteins that regulate vital biological functions that are impaired in various disease states. Targacept's lead program, TC-5214, is being co-developed with AstraZeneca and is in Phase 3 clinical trials as an adjunct treatment for major depressive disorder. Targacept leverages its scientific leadership and proprietary drug discovery platform Pentad™ to generate novel small molecule product candidates to fuel its pipeline and attract significant collaborations with global pharmaceutical companies.Targacept’s news releases are available on its website at www.targacept.com.
236 articles about Targacept, Inc.
-
Catalyst Biosciences Completes Merger With Targacept And Creates A Protease-Based Hemostasis And Anti-Complement Company
8/21/2015
-
Targacept Announces Stockholder Approval Of Proposals Related To Merger With Catalyst Biosciences
8/19/2015
-
Targacept Declares Pre-closing Dividend In Connection With Its Merger With Catalyst Biosciences
8/5/2015
-
Targacept And Catalyst Biosciences Amend Definitive Merger Agreement
5/14/2015
-
Targacept Winces As Last Remaining Drug Candidate Flops in Phase II Trial
4/17/2015
-
Targacept Announces Negative Top-Line Results From Exploratory Study Of TC-6499 In Diabetic Gastroparesis
4/16/2015
-
Targacept Abandons Nictoine Focus for Alzheimer's
4/6/2015
-
Bay Area's Catalyst Biosciences to Merge With Unlucky Targacept
3/9/2015
-
Targacept, Inc. Reports Third Quarter 2014 Financial Results
11/5/2014
-
Targacept, Inc. To Report Third Quarter 2014 Financial Results On November 5, 2014
10/29/2014
-
KeraNetics, LLC Quadrupling Manufacturing Space With Plan To Move Into Targacept, Inc.'s Old Haunts
10/24/2014
-
AstraZeneca PLC Completely Cuts Ties With Targacept, Inc.
10/10/2014
-
Targacept, Inc. Reports Second Quarter 2014 Financial Results
8/6/2014
-
Targacept, Inc. To Report Second Quarter 2014 Financial Results On August 6, 2014
7/30/2014
-
Second Failure Of The Month As Targacept, Inc. Halts Development Of Bladder Drug, Shares Plunge
7/30/2014
-
Targacept, Inc. Stops Alzheimer's Drug Trial After It Fails Phase 2b Trial
7/16/2014
-
Targacept, Inc. Initiates Exploratory Study Of TC-6499 In Diabetic Gastroparesis
6/25/2014
-
Targacept, Inc. Stock Price Down On Disappointing Earnings
5/8/2014
-
Targacept, Inc. To Report First Quarter 2014 Financial Results On May 7, 2014
4/30/2014
-
Targacept, Inc. To Present At The 13th Annual Needham Healthcare Conference
4/2/2014